Torrington Parkinson’s Support Group Hosts 10th Annual ‘Walk in the Woods’

TORRINGTON – The Torrington Parkinson region support group will be hosting their tenth ‘Walk in the Woods’ for Parkinson’s disease at the White Memorial Conservation Center, Route 202 in Litchfield on September 19th. Registration begins at noon.

The walk begins at 1 p.m. along three routes of 0.5, 1, and 2 miles. Proceeds from the event will benefit local people with Parkinson’s disease and the Michael J. Fox Research Foundation, which works to improve treatments and find a cure for Parkinson’s disease.

Donations for Walk in the Woods can be made directly to TAPSG. Members say they hope to raise $ 25,000 for local programming for Parkinson’s patients, raise awareness of Parkinson’s in the community, provide an afternoon of exercise, fun and fun in the open. air at the White Memorial Conservation Center and contribute to Parkinson’s disease research through the Michael J. Fox Foundation for PD Research.

Families can picnic on the grounds throughout the afternoon. Family-friendly activities on the grounds, baked goods, paid designs and a silent auction will be provided, along with Litchfield Fire Department and a makeup stand.

Parkinson’s disease is a chronic, degenerative, and neurological disease that affects more than one million people in the United States. in our community and healthcare providers who are learning more about Parkinson’s disease and the needs of those affected, ”members said.

To download a Walk in the Woods registration form, visit, Where .

The Handbook: Everything You Need to Know About Parkinson’s Disease, the Fox Team and the Michael J. Fox Foundation for Parkinson’s Research.

1. It is estimated that five million people worldwide live with Parkinson’s disease. In the United States, 60,000 new cases will be diagnosed this year alone.

2. Currently, there is no way to accurately prevent or predict who will develop Parkinson’s disease. There is no known cure, and currently available treatments temporarily mask symptoms as the disease continues to worsen.

3. Our Mission: The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson’s disease through an aggressively funded research program and to ensuring the development of improved therapies for people living with Parkinson’s disease today. ‘hui.

4. Team Fox is the fundraising arm of the Michael J. Fox Foundation for Parkinson’s Disease Research. Each year, more than 1,800 Team Fox members around the world turn their passions and interests into unique fundraising events and sporting achievements.

5. Since its inception in 2006, members of Team Fox have raised $ 35 million for Parkinson’s disease research.

6. To date, the Michael J. Fox Foundation has funded over $ 450 million in Parkinson’s disease research, making us the largest nonprofit funder of Parkinson’s disease research. in the world. With seven PhD graduates, a MD, and several business strategists, we have the expertise to assess the most promising research opportunities and to determine which areas hold the most promise for improving the treatment of PD.

7. Eighty-nine cents of every dollar we raise goes directly to our research program efforts. The Michael J. Fox Foundation is not chapter-based and has no endowment. We are doing everything we can to accelerate as quickly and efficiently as possible the intellectual and financial resources in the hands of scientists. We are in business to go bankrupt in our lifetime by finding a cure.

8. Fox Trial Finder, an online clinical trial matching tool, was created to increase the flow of volunteer participants – both people with Parkinson’s disease and participants without the disease – in clinical trials that need it, accelerating progress towards breakthrough therapies and a cure. Fox Trial Finder matches volunteers with trials and facilitates connection with the trial team. By creating a profile, volunteers can receive alerts when new trials start recruiting volunteers that match their criteria.

9. The Parkinson’s Progression Markers Initiative (PPMI) is the Foundation’s $ 45 million flagship clinical study aimed at identifying biomarkers of the progression of Parkinson’s disease.

Virginia S. Braud